Abeona Therapeutics Inc (NASDAQ:ABEO) is Western Standard LLC's 3rd Largest Position

Western Standard LLC boosted its stake in Abeona Therapeutics Inc (NASDAQ:ABEO - Free Report) by 7.0% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,698,097 shares of the biopharmaceutical company's stock after acquiring an additional 110,998 shares during the period. Abeona Therapeutics accounts for 10.1% of Western Standard LLC's investment portfolio, making the stock its 3rd largest holding. Western Standard LLC owned about 3.92% of Abeona Therapeutics worth $10,732,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. acquired a new position in shares of Abeona Therapeutics during the third quarter valued at about $151,000. GSA Capital Partners LLP increased its position in Abeona Therapeutics by 54.3% in the 3rd quarter. GSA Capital Partners LLP now owns 96,092 shares of the biopharmaceutical company's stock valued at $607,000 after buying an additional 33,831 shares in the last quarter. Bank of New York Mellon Corp raised its stake in Abeona Therapeutics by 2.0% during the 2nd quarter. Bank of New York Mellon Corp now owns 121,453 shares of the biopharmaceutical company's stock worth $515,000 after buying an additional 2,434 shares during the period. abrdn plc boosted its holdings in Abeona Therapeutics by 158.8% in the third quarter. abrdn plc now owns 326,995 shares of the biopharmaceutical company's stock worth $2,067,000 after acquiring an additional 200,647 shares in the last quarter. Finally, Simplify Asset Management Inc. acquired a new stake in Abeona Therapeutics in the second quarter valued at approximately $1,732,000. Institutional investors and hedge funds own 80.56% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on the company. HC Wainwright reiterated a "buy" rating and issued a $15.00 target price on shares of Abeona Therapeutics in a report on Monday, November 25th. Cantor Fitzgerald reissued an "overweight" rating and set a $18.00 target price on shares of Abeona Therapeutics in a research report on Tuesday, October 29th. Finally, StockNews.com upgraded shares of Abeona Therapeutics from a "sell" rating to a "hold" rating in a report on Thursday, November 28th.

Abeona Therapeutics Stock Up 0.2 %

NASDAQ:ABEO traded up $0.01 during trading hours on Friday, hitting $6.03. 115,621 shares of the company traded hands, compared to its average volume of 424,476. The company has a quick ratio of 6.12, a current ratio of 6.12 and a debt-to-equity ratio of 0.31. The company has a market cap of $262.12 million, a PE ratio of -2.24 and a beta of 1.44. The firm's 50-day simple moving average is $6.28 and its 200-day simple moving average is $5.39. Abeona Therapeutics Inc has a one year low of $3.05 and a one year high of $9.01.

About Abeona Therapeutics

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.